Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
38 studies found for:    Transverse Myelitis
Show Display Options
Rank Status Study
21 Enrolling by invitation An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder
Intervention: Biological: eculizumab
22 Recruiting A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study)
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: Eculizumab
23 Completed A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)
Conditions: Neuromyelitis Optica;   Myelitis, Transverse;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System
Intervention: Drug: Mitoxantrone
24 Recruiting The French Multiple Sclerosis Registry
Conditions: Multiple Sclerosis;   Neuromyelitis Optica Spectrum Disorders
Intervention:
25 Completed Neuromyelitis Optica (NMO) & Cetirizine
Condition: Neuromyelitis Optica
Intervention: Drug: cetirizine
26 Recruiting Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD
Condition: Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
Interventions: Drug: SA237;   Drug: Placebo
27 Recruiting Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD
Conditions: Neuromyelitis Optica (NMO);   NMO Spectrum Disorder (NMOSD)
Interventions: Drug: SA237;   Drug: Placebo
28 Active, not recruiting Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
Condition: Neuromyelitis Optica
Intervention: Procedure: AHSCT
29 Completed
Has Results
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
Conditions: Neuromyelitis Optica;   Devic's Disease
Intervention: Drug: Eculizumab
30 Recruiting Hematopoietic Stem Cell Transplant in Devic's Disease
Condition: Devic's Disease
Intervention: Procedure: Hematopoietic stem cell transplantation
31 Active, not recruiting Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder
Condition: Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: Bortezomib
32 Enrolling by invitation Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients
Conditions: Neuromyelitis Optica Spectrum Disorders;   Mycophenolate Mofetil;   Efficacy and Safety
Interventions: Drug: Mycophenolate mofetil;   Drug: Prednisone
33 Recruiting A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Condition: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (NMO/NMOSD)
Interventions: Biological: MEDI-551;   Other: Placebo
34 Unknown  Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorders
Intervention: Drug: Mitoxantrone
35 Unknown  Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
Condition: Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: NPB-01
36 Unknown  Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders
Conditions: Devic's Syndrome;   Devic's Neuromyelitis Optica;   Devic Syndrome;   Devic's Disease;   Devic Disease
Intervention: Biological: Autologous mesenchymal stem cells
37 Recruiting Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
Conditions: Multiple Sclerosis;   Neuromyelitis Optica Spectrum Disorders
Intervention: Other: Magnetic Resonance Imaging
38 Recruiting Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B
Conditions: Multiple Sclerosis;   Neuromyelitis Optica
Intervention: Biological: Tolerogenic Dendritic cells loaded with myelin peptides

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-38) Next Page   
Study has passed its completion date and status has not been verified in more than two years.